Pharma partner Presage acquires a clinical candidate of its own

Presage Biosciences, a popular partner for oncology drug developers, is wading into clinical development of its own, in-licensing a candidate and using its technology to spotlight potential combination therapies. The Seattle biotech acquired the rights to voruciclib, an oral CDK inhibitor, from India's Piramal Enterprises. Presage now plans to use its proprietary CIVO technology, which allows for the testing of cancer combinations on living tumors, to identify a path forward with the drug. To date, the company's development platform has helped it land agreements with Takeda and Celgene ($CELG). More

Suggested Articles

The biotech aims to differentiate itself with technology that enables the insertion of large DNA sequences without the use of viral vectors. 

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.

The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.